{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=2", "query": { "condition": "Differentiation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T23:43:25.781Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01146210", "title": "Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Fanconi Anemia", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Anemia With Ringed Sideroblasts", "Secondary Myelodysplastic Syndromes", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 20, "start_date": "2009-05", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "Monrovia, California", "locations": [ { "city": "Monrovia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01146210" }, { "nct_id": "NCT05746208", "title": "Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Well-Differentiated Neuroendocrine Carcinoma", "High Grade Neuroendocrine Carcinoma, Any Site" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Hyperpolarized 13C-Pyruvate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-07-17", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05746208" }, { "nct_id": "NCT00095797", "title": "XK469R in Treating Patients With Refractory Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "R(+)XK469", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095797" }, { "nct_id": "NCT04713046", "title": "Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HPV 16+ Recurrent or Metastatic Cancer" ], "interventions": [ { "name": "CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16", "type": "BIOLOGICAL" }, { "name": "Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-10-18", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04713046" }, { "nct_id": "NCT01870596", "title": "Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "CHK1 Inhibitor SCH 900776", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2013-05", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Baltimore, Maryland + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870596" }, { "nct_id": "NCT01413113", "title": "Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Papillary Thyroid Cancer", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Papillary Thyroid Cancer", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Papillary Thyroid Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "iodine I 131", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-12", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413113" }, { "nct_id": "NCT00045435", "title": "Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 17, "start_date": "2002-04", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 2, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045435" }, { "nct_id": "NCT04035226", "title": "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2019-08-02", "completion_date": "2022-10-27", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 12, "location_summary": "Glendale, California • Greenbrae, California • Weeki Wachee, Florida + 9 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Weeki Wachee", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035226" }, { "nct_id": "NCT01062152", "title": "Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Ezatiostat Hydrochloride", "type": "DRUG" }, { "name": "Lenalidomide (Revlimid®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-11", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01062152" }, { "nct_id": "NCT00709878", "title": "Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Skin Rash" ], "interventions": [ { "name": "Skin Biopsy of Skin Rash Secondary to EGFRI Use", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 32, "start_date": "2008-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-07-22T23:43:25.781Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709878" } ] }